ePrints

Endpoints and other considerations in phase I studies of targeted anticancer therapy: Recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies (MDICT)

Lookup NU author(s): Professor Alan Calvert

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.

Abstract

Oncology drug development has seen a paradigm shift in the past decade from traditional cytotoxic agents to molecular targeted therapies. Given the different mechanisms and toxicities of these agents, drug development methodology may also require novel approaches. To address emerging issues in oncology drug development the 'Methodology for the Development of Innovative Cancer Therapies' (MDICT) task force was established to provide a forum for academic leaders involved in cancer drug development to discuss methodological issues inherent to the study of targeted anticancer therapy. At the inaugural MDICT meeting in 2006, discussion focused on the most appropriate primary endpoints for first-in-man phase I studies of targeted anticancer agents and organisational issues of such studies. This report summarises the scientific reviews and discussions as well as the recommendations regarding phase I trial design formulated by the MDICT task force. © 2007 Elsevier Ltd. All rights reserved.

Publication metadata

Author(s): Booth C, Calvert AH, Giaccone G, Lobbezoo M, Seymour L, Eisenhauer E

Publication type: Article

Publication status: Published

Journal: European Journal of Cancer

Year: 2008

Volume: 44

Issue: 1

Pages: 19-24

ISSN (print): 0959-8049

ISSN (electronic):

Publisher: Pergamon

URL: http://dx.doi.org/10.1016/j.ejca.2007.07.034

DOI: 10.1016/j.ejca.2007.07.034

PubMed id: 17890079

Altmetrics

Share